- PRICING
- LIVE QUOTES
- LEARN
- HELP
EN
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here is one cash-producing company that reinvests wisely to drive long-term success and two best left off your watchlist.
Two Stocks to Sell:
FormFactor (FORM)
Trailing 12-Month Free Cash Flow Margin: 4.4%
With customers across the foundry and fabless markets, FormFactor (NASDAQ:FORM) is a US-based provider of test and measurement technologies for semiconductors.
Why Do We Think Twice About FORM?
- Sales trends were unexciting over the last five years as its 3.1% annual growth was below the typical semiconductor company
- High input costs result in an inferior gross margin of 41.4% that must be offset through higher volumes
- Lacking free cash flow margin got worse over the last five years as its investment needs accelerated
FormFactor is trading at $115.25 per share, or 46.1x forward P/E. If you’re considering FORM for your portfolio, see our FREE research report to learn more.
Supernus Pharmaceuticals (SUPN)
Trailing 12-Month Free Cash Flow Margin: 10.6%
With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.
Why Are We Hesitant About SUPN?
- 5.9% annual revenue growth over the last five years was slower than its healthcare peers
- Smaller revenue base of $776.9 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Supernus Pharmaceuticals’s stock price of $47.70 implies a valuation ratio of 18.8x forward P/E. To fully understand why you should be careful with SUPN, check out our full research report (it’s free).
One Stock to Buy:
Trane Technologies (TT)
Trailing 12-Month Free Cash Flow Margin: 14.5%
With low-pressure heating systems as its first product, Trane (NYSE:TT) designs, manufactures, and sells HVAC and refrigeration systems, the former to commercial and residential building customers and the latter to commercial truck manufacturers.
Why Should You Buy TT?
- Impressive 11% annual revenue growth over the last five years indicates it’s winning market share this cycle
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 17.6% exceeded its revenue gains over the last two years
- Free cash flow margin jumped by 8.4 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
At $476.50 per share, Trane Technologies trades at 31.4x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.